Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $40.77M, compared with -$37.39M a year earlier. Trailing-twelve-month net income was $165.86M. Over 3 fiscal years it compounded at -48.4% a year.
Context
- Net income amounted to 8.1% of revenue in FY2025, up 7.9 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of $226.93M (+844.9%) for the fiscal year ending Dec 2026, a slowdown from the +2629.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $40.77M-33.6% QoQ
- Last fiscal yearDec 2025
- $24.02M+2629.2% YoY
- LTMMar 2026
- $165.86M+628.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 24.02M USD
- Year-over-year change
- +2629.2%
- 4-year CAGR
- -53.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.02M | +2629.2% |
| FY2024 | 2024-12-31 | 880K | +100.1% |
| FY2023 | 2023-12-31 | (1B) | -672.5% |
| FY2022 | 2022-12-31 | 175.07M | -66.9% |
| FY2021 | 2021-12-31 | 528.45M | — |
Net Income vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's LTM Mar 2026 net income of $165.86M is the 2nd largest of the 3 companies compared; the peer median is $160.96M.
- Its year-over-year change of +628.0% is the highest of 3, against a peer median of +42.6%.
- Net income amounts to 45.9% of revenue for IRWD, versus a peer median of 152.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $263.86M | +77.1% | +22.8% | 291.6% | |
| LTM Mar 2026 | $165.86M | +628.0% | -48.4% | 45.9% | |
| LTM Mar 2026 | $58.06M | +8.0% | -2.9% | 13.6% | |
| Peer median (excluding IRWD) | $160.96M | +42.6% | +10.0% | 152.6% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.45M | 175.07M | (1B) | 880K | 24.02M |
| Depreciation & Amortization | 1.5M | 1.42M | 1.58M | 2.01M | 1.88M |
| Deferred Income Tax | (333.29M) | 65.74M | 72.64M | 68.09M | 40.8M |
| Stock-Based Compensation | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M |
| Change in Working Capital | 17.73M | 2.82M | 11.28M | 739K | 39.65M |
| Accounts Receivables | 7.71M | 7.99M | 924K | 47.24M | 35.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.64M) | (8.12M) | 12.38M | (20.21M) | 6.2M |
| Other Working Capital | 12.66M | 2.94M | (2.03M) | (26.29M) | (1.7M) |
| Other Non-Cash Items | 25.23M | 1.67M | 1.07B | 1.98M | 3.45M |
| Operating Cash Flow | 261.9M | 273.76M | 183.43M | 103.55M | 127.04M |
| Capital Expenditures | (265K) | (136K) | (273K) | (142K) | (34K) |
| Acquisitions (Net) | 0 | 0 | (1.03B) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (265K) | (136K) | (1.03B) | (142K) | (34K) |
| Debt Repayment | 0 | (120.7M) | 300M | (115M) | 0 |
| Common Stock Issued | 19.58M | 9.54M | 6.36M | 11.01M | 216K |
| Common Stock Repurchased | (24.13M) | (126.39M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.58M | 9.54M | (29.2M) | (2.98M) | 0 |
| Financing Cash Flow | (4.55M) | (237.55M) | 277.16M | (106.97M) | 216K |
| Effect of Forex Changes | 0 | 0 | (53K) | (32K) | (329K) |
| Net Change in Cash | 257.08M | 36.07M | (565.78M) | (3.6M) | 126.9M |
| Free Cash Flow | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.